Last reviewed · How we verify
TBC-MVA and TBC-FPV — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
TBC-MVA and TBC-FPV (TBC-MVA and TBC-FPV) — National Institute of Allergy and Infectious Diseases (NIAID).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TBC-MVA and TBC-FPV TARGET | TBC-MVA and TBC-FPV | National Institute of Allergy and Infectious Diseases (NIAID) | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TBC-MVA and TBC-FPV CI watch — RSS
- TBC-MVA and TBC-FPV CI watch — Atom
- TBC-MVA and TBC-FPV CI watch — JSON
- TBC-MVA and TBC-FPV alone — RSS
Cite this brief
Drug Landscape (2026). TBC-MVA and TBC-FPV — Competitive Intelligence Brief. https://druglandscape.com/ci/tbc-mva-and-tbc-fpv. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab